Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share

v3.22.0.1
Earnings (Loss) Per Common Share
6 Months Ended
Dec. 31, 2021
Earnings (Loss) Per Common Share [Abstract]  
Earnings (Loss) Per Common Share

16.   Earnings (Loss) Per Common Share

Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of common stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):

Three Months Ended

Six Months Ended

December 31, 

December 31, 

    

2021

    

2020

2021

    

2020

Basic and diluted numerator:

Net loss attributable to iBio, Inc.

    

$

(11,920)

    

$

(8,129)

$

(20,859)

    

$

(15,662)

Preferred stock dividends – iBio CMO Preferred Tracking Stock

 

(22)

 

(65)

 

(88)

 

(131)

Net loss available to iBio, Inc. stockholders

$

(11,942)

$

(8,194)

$

(20,947)

$

(15,793)

 

 

 

 

Basic and diluted denominator:

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding

 

217,990

 

188,087

 

217,933

 

175,264

 

 

 

 

Per share amount

$

(0.05)

$

(0.04)

$

(0.10)

$

(0.09)

In Fiscal 2021 and Fiscal 2020, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of December 31, 2021, and 2020, shares issuable which could potentially dilute future earnings were as follows:

December 31, 

    

2021

    

2020

(in thousands)

Stock options

 

14,943

 

4,251

Restricted stock units

 

768

 

349

Warrant issued under the Transaction

1,290

Shares excluded from the calculation of diluted loss per share

 

17,001

 

4,600